The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans
Open accessAbstract
Increased hepcidin production is key to the development of anemia of inflammation. We investigated whether lexaptepid, an antihepcidin l-oligoribonucleotide, prevents the decrease in serum iron during experimental human endotoxemia. This randomized, double-blind, placebo-controlled trial was carried out in 24 healthy males. At T = 0 hours, 2 ng/kg Escherichia coli lipopolysaccharide was intravenously administered, followed by an intravenous injection of 1.2 mg/kg lexaptepid or placebo at T = 0.5 hours. The lipopolysaccharide-induced inflammatory response was similar in subjects treated with lexaptepid or placebo regarding clinical and biochemical parameters. At T = 9 hours, serum iron had increased by 15.9 ± 9.8 µmol/L from baseline in lexaptepid-treated subjects compared with a decrease of 8.3 ± 9.0 µmol/L in controls (P < .0001). This study delivers proof of concept that lexaptepid achieves clinically relevant hepcidin inhibition enabling investigations in the treatment of anemia of inflammation. This trial was registered at www.clinicaltrial.gov as #NCT01522794.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some of these treatments are already being evaluated in clinical trials [153–158].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [154]
The cited source says what the claim attributes to it.
In the citing paper
“A recent study in humans demonstrated that spiegelmer-based hepcidin neutralization during experimental endotoxemia can prevent induction of hypoferremia [53].”
From Rapidly Escalating Hepcidin and Associated Serum Iron Starvation Are Features of the Acute Response to Typhoid Infection in Humans (2015) · cites this paper as [53]
In the citing paper
“Moreover, NOX-H94 prevented hypoferremia in experimental human endotoxemia with LPS-injected volunteers (Van Eijk et al., 2014) (ClinicalTrials.gov Identifier: NCT01522794).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Van Eijk et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Iron metabolism in the anemia of chronic disease
Weiss, G. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.08.006 · Cited by 322 · cited 2×
“The dysregulation of iron homeostasis is central to the pathogenesis of anemia of inflammation.(1,3) A redistribution of iron to the cells of the reticuloendothelial systemoccurs, with hepcidin as a central mediator.”
BackgroundPathogenesis and treatment of anaemia of chronic disease
Weiss, G. (2002) · Blood Reviews · doi:10.1054/blre.2002.0193 · Cited by 277 · cited 1×
“Anemia of inflammation is the most prevalent form of anemia in a hospital setting,(1) occurring in a variety of acute and chronic inflammatory diseases.(2) The dysregulation of iron homeostasis is central to the pathogenesis of anemia of inflammation.”
BackgroundSasu, B. J., Cooke, K. S., Arvedson, T. L., Plewa, C., Ellison, A. R., Sheng, J., Winters, A., Juan, T., Li, H., Begley, C. G., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245977 · Cited by 251
Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats
Theurl, I., Schroll, A., Sonnweber, T., Nairz, M., Theurl, M., Willenbacher, W., Eller, K., Wolf, D., Seifert, M., Sun, C. C., et al. (2011) · Blood · doi:10.1182/blood-2011-03-345066 · Cited by 189
Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation
Roy, C. N., Mak, H. H., Akpan, I., Losyev, G., Zurakowski, D., & Andrews, N. C. (2007) · Blood · doi:10.1182/blood-2006-10-051755 · Cited by 178 · cited 1×
“Hepcidin induces internalization and degradation of the iron-exporting channel ferroportin on duodenal enterocytes and iron-storing cells,(4) thereby preventing the export of iron into the circulation and causing iron-restricted erythropoiesis.(5) Hence, hepcidin inhibition may be an attractive therapeutic interventio…”
BackgroundInhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation
Steinbicker, A. U., Sachidanandan, C., Vonner, A. J., Yusuf, R. Z., Deng, D. Y., Lai, C. S., Rauwerdink, K. M., Winn, J. C., Saez, B., Cook, C. M., et al. (2011) · Blood · doi:10.1182/blood-2010-10-313064 · Cited by 173
Hsieh, M. M., Linde, N. S., Wynter, A., Metzger, M., Wong, C., Langsetmo, I., Lin, A., Smith, R., Rodgers, G. P., Donahue, R. E., et al. (2007) · Blood · doi:10.1182/blood-2007-02-073254 · Cited by 171
Schwoebel, F., van Eijk, L. T., Zboralski, D., Sell, S., Buchner, K., Maasch, C., Purschke, W. G., Humphrey, M., Zöllner, S., Eulberg, D., et al. (2013) · Blood · doi:10.1182/blood-2012-09-456756 · Cited by 158 · cited 1×
“Lexaptepid has proven effective in counteracting hepcidin’s effects in animal models, including an IL-6–induced anemia model in cynomolgus monkeys.(11) In the present study, we extend the concept of hepcidin inhibition to humans for the first time.”
BackgroundSelf-citation
Cited by
Lopez, A., Cacoub, P., Macdougall, I. C., & Peyrin-Biroulet, L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)60865-0 · Cited by 1,492
Targeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352
The multifaceted role of iron in renal health and disease
van Swelm, R. P. L., Wetzels, J. F. M., & Swinkels, D. W. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0197-5 · Cited by 275
Self-citationThe Regulation of Iron Absorption and Homeostasis.
Wallace, D. F. (2016) · PubMed · Cited by 365
Hepcidin regulation in the anemia of inflammation
Wang, C.-Y., & Babitt, J. L. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000236 · Cited by 250
Metadata
- Authors
- van Eijk, L. T., John, A. S. E., Schwoebel, F., Summo, L., Vauléon, S., Zöllner, S., Laarakkers, C. M., Kox, M., van der Hoeven, J. G., Swinkels, D. W., Riecke, K., & Pickkers, P.
- Affiliations
- Department of Intensive Care Medicine, and
- Radboud University Nijmegen (NL)
- Noxxon Pharma (Germany) (DE)
- NOXXON Pharma AG, Berlin, Germany;
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-10-23
- Volume
- 124
- Issue
- 17
- Pages
- 2643-2646
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC4208279
- OpenAlex
- W2129185886
- Cited by
- 110
- References
- 19
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 9 · 2020: 14 · 2019: 10 · 2018: 12 · 2017: 18 · 2016: 17 · 2015: 10 · 2014: 3
- FWCI
- 11.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Bundesministerium für Bildung und Forschung
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- serum iron, anemia of chronic disease, endotoxemia, lipopolysaccharide, iron metabolism
- MeSH terms
- Adolescent, Adult, Anti-Inflammatory Agents, C-Reactive Protein, Double-Blind Method, Humans, Inflammation, Injections, Intravenous, Iron, Leukocyte Count, Lipopolysaccharides, Male, Metabolic Clearance Rate, Oligoribonucleotides, Tumor Necrosis Factor-alpha, Interleukin-6, Interleukin-10, Treatment Outcome, Endotoxemia, Interleukin 1 Receptor Antagonist Protein, Young Adult, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. https://app.cochat.ai/papers/10.1182/blood-2014-03-559484
- The paper
- van Eijk, L. T., John, A. S. E., Schwoebel, F., Summo, L., Vauléon, S., Zöllner, S., Laarakkers, C. M., Kox, M., van der Hoeven, J. G., Swinkels, D. W., Riecke, K., & Pickkers, P. (2014). Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood. https://doi.org/10.1182/blood-2014-03-559484
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.